BiotechTube

Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + Thioguanine

Phase 2Recruiting
2 views this week 0 watching⚡ Active🧪Featured in Gene & Cell Therapy Watch
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

T-cell Acute Lymphoblastic Leukemia

Conditions

T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia

Trial Timeline

Dec 27, 2024 → Dec 1, 2033

NCT ID
NCT06390319

About Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + Thioguanine

Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + Thioguanine is a phase 2 stage product being developed by AbbVie for T-cell Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06390319. Target conditions include T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia.

What happened to similar drugs?

5 of 10 similar drugs in T-cell Acute Lymphoblastic Leukemia were approved

Approved (5) Terminated (1) Active (4)
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
🔄E7777 9 mcg/kgEisaiPhase 3
✅ONTAKEisaiApproved
❌E7777EisaiPhase 3
✅MogamulizumabKyowa KirinApproved
🔄KW-0761 + VorinostatKyowa KirinPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06390319Phase 2Recruiting

Competing Products

20 competing products in T-cell Acute Lymphoblastic Leukemia

See all competitors
ProductCompanyStageHype Score
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
31
Valemetostat TosylateDaiichi SankyoPhase 2
35
Valemetostat TosylateDaiichi SankyoPhase 2
39
E7777EisaiPhase 2
35
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
43
ONTAKEisaiApproved
43
Denileukin diftitox + Cyclophosphamide + Doxorubicin + Vincristine + PrednisoneEisaiPhase 2
35
Ontak + CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapyEisaiPhase 2
35
Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitoxEisaiPhase 2
27
RemitoroEisaiPre-clinical
26
denileukin diftitox (E7777)EisaiPhase 1
29
E7777 9 mcg/kgEisaiPhase 3
40
ONTAKEisaiApproved
43
E7777EisaiPhase 3
32
KW-0761Kyowa KirinPhase 2
35
KW-0761 + Pralatrexate + gemcitabine plus oxaliplatin + DHAPKyowa KirinPhase 2
35
KK2223Kyowa KirinPhase 1
36
MogamulizumabKyowa KirinApproved
47
KW-0761 (mogamulizumab)Kyowa KirinPhase 2
35
KW-0761Kyowa KirinPhase 2
35